About Indivior PLC (IZQVF) β Dividend Analysis 2026
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Is IZQVF a good dividend investment in 2026?
IZQVF offers a 9.54% forward yield with a 50% payout ratio. Strand Safety Score: 60/100 (Moderate Risk). The 5-year dividend CAGR of 0% is modest β investors should weigh current income against growth alternatives.
IZQVF DRIP calculator β what's the difference?
With DRIP on a $10,000 investment over 10 years, your IZQVF portfolio grows to $11.25M vs $10.25M without reinvestment. This is the compound interest effect in action.
IZQVF dividend growth history & forecast
IZQVF has grown its dividend by 0% over the last year and 0% annually over 5 years. At this pace, an investor who holds for 10+ years will see their yield on cost grow substantially above the current 9.54%.
Company generates negative FCF ($-93M) β borrowing to pay dividends
Debt Leverage0.0Γ Debt/EBITDA
30 / 30 pts
30/30
Debt/EBITDA 0.0Γ β low leverage, balance sheet is strong
Earnings Momentum+0.2B β +0.0B β -0.1B
30 / 30 pts
30/30
Net income grew for 2 consecutive years β strong earnings momentum
OVERALL ASSESSMENT
Dividend at moderate risk β monitor coverage and debt closely.
STRAND SCORE
60
/100
Strand Safety Scoreβ’ is proprietary to DividendFlow. Inputs: FCF, Debt/EBITDA, Net Income from SEC filings via FMP. Not financial advice. N/A for ETFs, pre-revenue companies, and tickers without income statements.
π IZQVF Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold IZQVF.
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
π― IZQVF Income Goal & Break-Even
Dividend Break-Even
13yr
Years for dividends to fully repay your IZQVF investment of $20.97/share (πΊπΈ US Taxable (15%) Β· 15.00% tax)
$10K invested Β· 10 Years
Dividends earned (DRIP)
$8.6K
Lost to inflation (2.8% CPI)
β$2.5K
Real purchasing power gain
$6.2K
12-month CPI (US BLS via FMP economic-indicators).
How much do I need to invest in IZQVF for:
Shares needed
14,118
Capital required
$296,054
Monthly income
$2,000
Based on current dividend of $2.00/share/yr Β· πΊπΈ US Taxable (15%) Β· static projection (no growth assumed).
π IZQVF Dividend Payment Schedule
IZQVF pays quarterly β 4 times per year. Next ex-div: TBD.
Jan
Feb
Mar
π°
Apr
May
Jun
π°
Jul
Aug
Sep
π°
Oct
Nov
Dec
π°
10 shares
$4.25 / payment
$17.00 / year after tax
100 shares
$42.50 / payment
$170.00 / year after tax
1,000 shares
$425.00 / payment
$1700.00 / year after tax
π IZQVF vs Healthcare Benchmarks
How IZQVF compares to typical Healthcare averages.
Benchmark: Healthcare
Dividend Yieldβ²+6.74% vs sectorBetter
IZQVF
9.54%
avg
2.80%
5Y Dividend CAGRβΌ-6.80% vs sectorBelow avg
IZQVF
0.00%
avg
6.80%
Payout Ratioβ²-5.00% vs sectorBetter
IZQVF
50.00%
avg
55.00%
Benchmarks: S&P 500 sector averages (2024β2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for IZQVF sourced from FMP /financial-growth endpoint β real data, not estimates.
ποΈ IZQVF Insider Activity
β² 3 Buys
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
Insider
Title
Type
Date
Shares
Price
Total Value
Preblick Ryan
officer: Chief Financial Officer
M-Exempt
2026-03-14
6,302
β
β
Preblick Ryan
officer: Chief Financial Officer
F-InKind
2026-03-14
2,843
$31.11
$88.4K
Preblick Ryan
officer: Chief Financial Officer
M-Exempt
2026-03-14
6,302
β
β
Ryan Barbara
director
Buy
2026-03-13
8
$31.09
$249.00
Kingsley Stuart A
director
Buy
2026-03-06
940
$31.86
$30.0K
Ryan Barbara
director
Buy
2026-03-09
31
$32.56
$1.0K
Anderson Woodrow D
officer: Chief Accounting Officer
M-Exempt
2026-03-03
18,364
β
β
Anderson Woodrow D
officer: Chief Accounting Officer
M-Exempt
2026-03-03
5,946
β
β
Anderson Woodrow D
officer: Chief Accounting Officer
F-InKind
2026-03-03
2,682
$31.98
$85.8K
Anderson Woodrow D
officer: Chief Accounting Officer
F-InKind
2026-03-03
8,283
$31.98
$264.9K
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
π‘
Net Insider Sentiment: Neutral3 buys Β· 0 sells Β· last 90 days
Net: +$31.2K
π About This Data
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the IZQVF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer β